ASBPW Aspire Biopharma Holdings, Inc. - Warrant
$0.02
Price · May 19, 2026
Fundamentals as of May 15, 2026
52W Range
$0–$1
0% of range
Analyst Rating
—
Price Target
—
P/E (TTM)
—
ROE
306.1%
Net Profit Margin
-394725.1%
ASBPW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.02
Market Cap
—
P/E (TTM)
—
EPS (TTM)
$-16.38
Revenue (TTM)
$6.2K
Div Yield
—
ROE
306.1%
Debt/Equity
—
52W Range
$0 – $1
ASBPW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$6.2K
2025-12-31
→
2025-12-31
EPS
$-16.38
2024-12-31
→
2025-12-31
Free Cash Flow
—
Margins
-394725.1%
2025-12-31
→
2025-12-31
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ASBPW
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ASBPW
Peer Median
Gross Margin
-1.9%
—
Operating Margin
-312017.0%
—
Net Profit Margin
-394725.1%
—
ROA
-3353.2%
—
ROE
306.1%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ASBPW
Peer Median
Current Ratio
0.2
—
Quick Ratio
0.1
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ASBPW
Peer Median
Net Income YoY
33.7%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ASBPW
Peer Median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 14
| Metric | Trend | 2025 |
|---|---|---|
| Revenue | $6.2K | |
| Cost of Revenue | $6.3K | |
| Gross Profit | $-116 | |
| R&D Expense | $923.9K | |
| SG&A Expense | $18M | |
| Operating Expenses | $19M | |
| Operating Income | $-19M | |
| Other Non-op | $-5M | |
| Pretax Income | $-24M | |
| Net Income | $-24M | |
| EPS (Diluted) | $-16.38 | |
| Shares (Basic) | 1,494,956 | |
| Shares (Diluted) | 1,494,956 | |
| EBITDA | $-19M |
Balance Sheet 15
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $1M | |
| Inventory | $253.2K | |
| Prepaid Expense | $55.1K | |
| Current Assets | $1M | |
| Total Assets | $1M | |
| Accounts Payable | $1M | |
| Accrued Liabilities | $1M | |
| Current Liabilities | $8M | |
| Total Liabilities | $8M | |
| Common Stock | $12 | |
| Paid-in Capital | $21M | |
| Retained Earnings | $-27M | |
| Stockholders' Equity | $-6M | |
| Liabilities + Equity | $1M | |
| Shares Outstanding | 117,780 |
Cash Flow 4
| Metric | Trend | 2025 |
|---|---|---|
| Stock-based Comp | $14M | |
| Operating Cash Flow | $-5M | |
| Financing Cash Flow | $6M | |
| Net Change in Cash | $1M |
Profitability 7
| Metric | Trend | 2025 |
|---|---|---|
| Gross Margin | -1.9% | |
| Operating Margin | -312017.0% | |
| Net Margin | -394725.1% | |
| Pretax Margin | -394725.1% | |
| EBITDA Margin | -312017.0% | |
| ROA | -3353.2% | |
| ROE | 306.1% |
Liquidity & Solvency 2
| Metric | Trend | 2025 |
|---|---|---|
| Current Ratio | 0.2 | |
| Quick Ratio | 0.1 |
Efficiency 2
| Metric | Trend | 2025 |
|---|---|---|
| Asset Turnover | 0.0 | |
| Inventory Turnover | 0.0 |
Valuation (TTM) 2
| Metric | Trend | 2025 |
|---|---|---|
| Revenue TTM | $6.2K | |
| Net Income TTM | $-24M |
Income Statement 16
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue | $28.4K | $4.3K | $1.9K | |
| Cost of Revenue | $22.6K | $5.3K | $1.1K | |
| Gross Profit | $5.8K | $-1.0K | $884 | |
| R&D Expense | $296.7K | $100.0K | $207.9K | |
| SG&A Expense | $1M | $2M | $513.0K | |
| Operating Expenses | $2M | $2M | $1M | |
| Operating Income | $-2M | $-2M | $-1M | |
| Interest Income | $5.0K | · | · | |
| Other Non-op | $-2M | $-3M | $-705.0K | |
| Pretax Income | $-3M | · | · | |
| Net Income | $-3M | $-5M | $-2M | |
| EPS (Basic) | $-20.57 | · | $-0.04 | |
| EPS (Diluted) | $-20.57 | $-15.95 | $-0.04 | |
| Shares (Basic) | 156,685 | -44,163,740 | 49,525,970 | |
| Shares (Diluted) | 156,685 | -44,163,740 | 49,525,970 | |
| EBITDA | $-2M | · | $-1M |
Balance Sheet 15
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $6M | $1M | $2M | |
| Inventory | $370.0K | $253.2K | $35.4K | |
| Prepaid Expense | $890.1K | $55.1K | $419.4K | |
| Current Assets | $7M | $1M | $2M | |
| Total Assets | $7M | $1M | $2M | |
| Accounts Payable | $857.9K | $1M | $1M | |
| Accrued Liabilities | $441.6K | $1M | $266.9K | |
| Current Liabilities | $3M | $8M | $14M | |
| Total Liabilities | $3M | $8M | $14M | |
| Common Stock | $17 | $353 | $5.0K | |
| Paid-in Capital | $34M | $21M | $11M | |
| Retained Earnings | $-30M | $-27M | $-23M | |
| Stockholders' Equity | $4M | $-6M | $-11M | |
| Liabilities + Equity | $7M | $1M | $2M | |
| Shares Outstanding | 167,470 | 3,533,408 | 49,525,970 |
Cash Flow 6
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Stock-based Comp | $13.4K | $0 | $0 | |
| Operating Cash Flow | $-3M | $-927.8K | $-1M | |
| Stock Issued | $9M | · | · | |
| Net Stock Activity | $9M | · | · | |
| Financing Cash Flow | $8M | $-16.5K | $3M | |
| Net Change in Cash | $5M | $-944.4K | $2M |
Profitability 7
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Gross Margin | 20.3% | · | 45.5% | |
| Operating Margin | -5806.0% | · | -59015.8% | |
| Net Margin | -11367.0% | · | -95337.1% | |
| Pretax Margin | -11367.0% | · | · | |
| EBITDA Margin | -5806.0% | · | -59015.8% | |
| ROA | -71.0% | · | -40.8% | |
| ROE | 157.8% | · | 20.6% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Current Ratio | 2.3 | · | 0.2 | |
| Quick Ratio | 1.9 | · | 0.1 |
Efficiency 2
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | · | 0.1 |
Valuation (TTM) 5
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|
| Net Income TTM | $-23M | · | $-21M | |
| Market Cap | $3.3K | · | · | |
| P/B | 0.0 | · | · | |
| P / Tangible Book | 0.0 | · | · | |
| P / Cash Flow | -0.0 | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $6.2K | — | — | — | — |
| Gross Margin % | -1.9% | — | — | — | — |
| Operating Margin % | -312017.0% | — | — | — | — |
| Net Income | $-24M | $-1M | $4M | $3M | $-25.5K |
| Diluted EPS | $-16.38 | $-1.90 | — | — | — |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 0.2 | 0.0 | 0.2 | 3.6 | — |
| Quick Ratio | 0.1 | — | — | 1.6 | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.